Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2019

Proffered paper session - Breast cancer

Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA

Date

23 Nov 2019

Session

Proffered paper session - Breast cancer

Presenters

Kyung-Hun Lee

Citation

Annals of Oncology (2019) 30 (suppl_9): ix13-ix19. 10.1093/annonc/mdz418

Authors

K. Lee1, S. Kim2, J. Sohn3, A. Goodwin4, T. Usari5, S. Lanzalone5, Y. Im6

Author affiliations

  • 1 Internal Medicine, Seoul National University Hospital, 03080 - Seoul/KR
  • 2 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 3 Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul/KR
  • 4 Medical Oncology, Concord Clinical School, University of Sydney, Sydney/AU
  • 5 Oncology, Pfizer, Milan/IT
  • 6 Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.